DiaMedica Therapeutics, Inc.

DiaMedica Therapeutics, Inc.

DI
Company Profile

DiaMedica Therapeutics, Inc.

Minneapolis, MN | Minnetonka, United States of America

Our Focus Overview Literature & Publications Pipeline Preeclampsia & Fetal Growth Restriction Acute Ischemic Stroke Clinical Trials ReMEDy2 Trial
0Products
0People
0Events
0Locations

Overview

Company details and contact information.

About

About DiaMedica Therapeutics, Inc. DiaMedica Therapeutics is a clinical-stage biopharma company developing DM199, a recombinant form of KLK1, to improve outcomes in ischemic stroke. DM199 is being evaluated in the Phase 2/3 ReMEDy2 clinical trial.

Address
301 Carlson Parkway Suite 210, Minneapolis, MN, 55305 | 301 Carlson Parkway, Minnetonka MN 55305, United States of America